CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) rose 6% during trading on Tuesday . The company traded as high as $45.10 and last traded at $44.62. Approximately 866,303 shares changed hands during trading, a decline of 60% from the average daily volume of 2,163,673 shares. The stock had previously closed at $42.09.
Analyst Upgrades and Downgrades
CRSP has been the topic of a number of research analyst reports. Citigroup decreased their price target on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a research report on Tuesday, February 18th. Chardan Capital decreased their price target on CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Barclays reduced their price objective on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a report on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. Finally, The Goldman Sachs Group reduced their price objective on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $71.75.
Get Our Latest Analysis on CRSP
CRISPR Therapeutics Trading Up 0.2%
The stock has a 50 day moving average price of $37.75 and a two-hundred day moving average price of $40.95. The company has a market cap of $3.57 billion, a price-to-earnings ratio of -9.46 and a beta of 1.75.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same period last year, the company posted ($1.43) earnings per share. The company's quarterly revenue was up 71.6% compared to the same quarter last year. On average, equities analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.
Insider Activity at CRISPR Therapeutics
In related news, insider Naimish Patel sold 3,932 shares of the company's stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the sale, the insider now owns 6,068 shares in the company, valued at $218,083.92. This represents a 39.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.30% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On CRISPR Therapeutics
Large investors have recently added to or reduced their stakes in the company. SVB Wealth LLC bought a new position in CRISPR Therapeutics during the 1st quarter worth about $25,000. Wood Tarver Financial Group LLC bought a new position in CRISPR Therapeutics during the 4th quarter worth about $30,000. Costello Asset Management INC bought a new position in CRISPR Therapeutics during the 1st quarter worth about $27,000. Ameriflex Group Inc. bought a new position in CRISPR Therapeutics during the 4th quarter worth about $36,000. Finally, Quantbot Technologies LP increased its holdings in CRISPR Therapeutics by 272.4% during the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company's stock worth $45,000 after purchasing an additional 978 shares in the last quarter. Institutional investors own 69.20% of the company's stock.
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Further Reading
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
